Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the viral vectors used in the gene therapy-based clinical trial in patients with Fanconi anemia. In this study, the authors demonstrate for the first time the production of blood cells derived from the patients genetically corrected stem cells. The work on Fanconi anemia patients is published in Nature Medicine : https://www.nature.com/articles/s41591-019-0550-z